Clinical Gastroenterology and Hepatology
Volume 1, Issue 1 , Pages 57-63, January 2003

An evidence-based approach to studies of gastrointestinal therapies☆☆☆★

  • Philip Schoenfeld

      Affiliations

    • Division of Gastroenterology, University of Michigan School of Medicine
    • Veteran Affairs Center for Excellence in Health Services Research, Ann Arbor, Michigan
    • ,
  • James Scheiman

      Affiliations

    • Division of Gastroenterology, University of Michigan School of Medicine

Full Text Available

  • Purchase this article for  31.50 USD

    Access is available for 24 hours.

    (Login or Register to purchase)

  • Subscribe to this title
  • Claim access now

    Current subscribers


    • ☆ Address requests for reprints to: Philip Schoenfeld, M.D., MSEd, MSc (Epi), Assistant Professor of Medicine, Gastroenterology Section (111D), VA Ann Arbor Healthcare System, 2215 Fuller Road, Ann Arbor, Michigan 48105.

    ☆☆ The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the Department of Veterans Affairs.

    ★ Dr. Schoenfeld is a consultant for Novartis Pharmaceuticals Corporation, Wyeth Laboratories, Merck, and AstraZeneca. Dr. Schoenfeld is on the Speaker's Bureau for AstraZeneca, Wyeth Laboratories, TAP Pharmaceuticals, Novartis Pharmaceuticals Corporation, Boehringer Ingelheim, and Merck, and he owns stock in Wyeth, Merck, and Glaxo Wellcome. Dr. Scheiman is a consultant for AstraZeneca, Merck, Nitromed, Novartis, and McNeil. Dr. Scheiman is on the Speaker's Bureau for AstraZeneca, TAP, Merck, Wyeth, Pfizer, and Boehringer Ingelheim, and he has received grant and research support from AstraZeneca, BykGolden, Pfizer, Merck, and SmithKline Beecham.

    PII: S1542-3565(03)70011-1

    doi:10.1053/jcgh.2003.50009

    Clinical Gastroenterology and Hepatology
    Volume 1, Issue 1 , Pages 57-63, January 2003